Globally Marketed Products

ANGIOX® (bivalirudin) is marketed in Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece,  Iceland, Ireland, Italy, Kazakhstan, Luxembourg, Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, and the United Kingdom.

ANGIOMAX® (bivalirudin) is marketed in Argentina, Australia, Canada, Chile, India, Israel, New Zealand, Peru and Venezuela.

In the European Union, we have marketing approval for KENGREXAL® (cangrelor), ORBACTIV® (oritavancin), and IONSYS® (fentanyl iontophoretic transdermal system).

CLEVIPREX® (clevidipine) has marketing approval in Australia, Austria, Belgium, Canada, France, Germany, Luxembourg, New Zealand, The Netherlands, Spain, Sweden, Switzerland and the United Kingdom.

Approved product indications, registrations, and presentations may differ between countries. Therefore, please contact Global Medical Information or appropriate regional office to obtain the most current registration details and approved product label.

Global Medical Information

Approved product indications, registrations, and presentations may differ between countries. Therefore, please contact the Global Medical Information or appropriate regional office to obtain the most current registration details and approved product label.